# Antibiotic Adjuvant: A Healthcare Software Company Addressing Antibiotic Resistance
Antibiotic Adjuvant is a healthcare technology company that develops software solutions to combat antibiotic resistance and reduce medication misuse in clinical settings.[1][3] Founded in 2015 and based in Gainesville, Florida, the company uses machine learning and data analytics to optimize antibiotic prescribing practices across healthcare facilities.[1][3]
Antibiotic Adjuvant builds SmartSteward, a software platform designed to address the critical problem of antibiotic overuse and misuse in hospitals and long-term care facilities.[3][4] The product operates on two levels: at the point of prescription, it provides physicians with decision-support tools to optimize antibiotic selection, and at the facility level, it coordinates antibiotic use across departments while adapting recommendations in real-time based on the facility's evolving microbial resistance patterns.[3]
The company serves healthcare providers—particularly hospitals and long-term care facilities—facing the dual challenge of treating infections effectively while preventing the emergence of antibiotic-resistant bacteria. By reducing inappropriate antibiotic use, SmartSteward addresses a major public health threat: antimicrobial resistance, which compromises the efficacy of existing antibiotics and increases treatment complications.[3][4]
Antibiotic Adjuvant operates at the intersection of two critical healthcare trends: the rise of antimicrobial resistance as a global health crisis and the increasing adoption of data analytics in clinical decision-making. The company's timing is particularly relevant given that antibiotic resistance has become a major concern in long-term care settings, where overuse is endemic.[4]
The broader field of antibiotic adjuvants—compounds that enhance antibiotic efficacy—has gained significant traction in recent years as a pharmaceutical strategy.[5] However, Antibiotic Adjuvant's software approach is distinct: rather than developing new chemical compounds, it uses informatics to maximize the effectiveness of existing antibiotics through smarter prescribing. This positions the company within the growing healthcare analytics and clinical decision-support software sector, where machine learning is increasingly deployed to improve outcomes and reduce costs.
Antibiotic Adjuvant addresses a problem with both immediate clinical urgency and long-term strategic importance. As healthcare systems face mounting pressure to combat resistance while reducing unnecessary medication use, software-based stewardship tools are likely to become standard infrastructure rather than optional add-ons. The company's ability to demonstrate measurable reductions in antibiotic misuse and facility-level resistance will be critical to scaling adoption across hospital networks and health systems.
The convergence of regulatory pressure, reimbursement incentives favoring quality metrics, and growing awareness of resistance risks creates a favorable environment for clinical decision-support solutions. Antibiotic Adjuvant's focus on the often-overlooked long-term care sector—where resistance problems are acute but technology adoption lags—represents both a near-term market opportunity and a potential entry point for broader healthcare system adoption.
